Survival meta-analysis from fifteen years of a standard systemic therapy in malignant pleural mesothelioma. The combined treatment of 150 kHz tumor treating fields (TTFields) and cisplatin or ...

THE therapeutic management of empyema of the pleura has been revised because of the recent favorable experiences with penicillin. The treatment by open drainage after rib resection has been the ...

Interventional pulmonologists are highly trained specialists who use advanced, non-surgical therapies to treat your respiratory system. Interventional pulmonologists have experience with a broad range ...

Human lungs on a dark background. 3D illustration. Vintage style. This story is part of a series exploring human anatomy and physiology complexities. Each story in this collection showcases ...

Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers have discovered a novel mechanism ...

Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers have discovered a novel mechanism ...

SYDNEY — One of the few randomized phase 3 trials ever conducted in mesothelioma has found that keyhole surgery did not improve survival when compared with the standard treatment of talc pleurodesis.

EFFUSION into the general pleural cavity is a frequent manifestation of congestive heart failure. On the other hand, pleural effusion localized in an interlobar space is not a common finding, since ...

Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).

Empyema often co-occurs with pneumonia and refers to the presence of pus in the pleural space. There is a range of therapeutic options available for the management of empyema, the primary aim being to ...

TOKYO & AUSTIN, Texas--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd, (“Taiho”) and Lung Therapeutics, Inc. (“Lung Tx”) announced today an exclusive license agreement of LTI-01, a recombinant human ...